QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan

Qiagen ( (QGEN) ) has provided an update.

On January 16, 2025, QIAGEN announced the completion details of a synthetic share repurchase plan to return up to approximately $300 million to shareholders by late January 2025. This plan, which combines a direct capital repayment with a reverse stock split, follows a previous $300 million return in early 2024 and is part of a commitment to return at least $1 billion to shareholders by 2028. Approved by shareholders in June 2024, the repurchase aims to enhance earnings per share by reducing outstanding shares by approximately 2.8%. The last trading day for pre-split shares is January 28, 2025, with post-split shares trading from January 29, 2025.

More about Qiagen

QIAGEN N.V., a Netherlands-based holding company, is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company offers technologies for isolating and processing DNA, RNA, and proteins, assay technologies, bioinformatics software, and automation solutions. QIAGEN serves over 500,000 customers worldwide in the Molecular Diagnostics (human healthcare) and Life Sciences sectors (academia, pharma R&D, and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide.

YTD Price Performance: 1.68%

Average Trading Volume: 856,341

Technical Sentiment Consensus Rating: Strong Sell

Current Market Cap: $10.11B

Learn more about QGEN stock on TipRanks’ Stock Analysis page.